GI Cancers

FDA Grants Two Fast Track Designations to Surufatinib in Pancreatic and Extrapancreatic NETs

April 17, 2020

The FDA granted two Fast Track designations to surufatinib for the treatment of both advanced and progressive pancreatic neuroendocrine tumors and extra-pancreatic NETs in patients who are not amenable for surgery, according to a press release from the developer, Chi-Med. The agent was previously granted Orphan Drug Designation by the FDA for this indication.

Liquid Biopsy Accurately Detects Early-Stage Pancreatic Ductal Adenocarcinoma

April 17, 2020

A liquid biopsy test with the ability to screen for a panel of biomarkers rather than just one can reportedly detect pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, in the early stages of disease.

Optimizing Treatment in Patients With Resectable Pancreatic Cancer

April 16, 2020

Vincent Picozzi, MD, discusses treatment for patients with pancreatic cancer who undergo surgery. Overall, the landscape lacks data on how to optimally sequence chemotherapy in patients with resectable disease.

Sequencing Therapy in Patients With Resectable Pancreatic Cancer Under Investigation

April 09, 2020

In an interview with Targeted Oncology, Vincent Picozzi, MD, discussed the findings that were presented at the 2020 GI Cancers Symposium for patients with pancreatic cancer and how the results could impact the treatment of this patient population. He also highlighted observations from other pancreatic cancer clinical trials and the evolution of the GI cancer landscape as a whole.

FDA Grants Pembrolizumab Priority Review for TMB-High Tumors

April 07, 2020

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Pembrolizumab Meets PFS Milestone for Patients with MSI-H/dMMR mCRC

April 06, 2020

Pembrolizumab demonstrated an improvement in progression-free survival in the first-line treatment of patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer, meeting one of the primary end points of the phase III KEYNOTE-177 trial.

Pembrolizumab Leads to Promising Outcomes in Advanced ASCC

April 06, 2020

Pembrolizumab demonstrated positive activity in patients with previously treated advanced anal squamous cell carcinoma, regardless of PD-L1 expression, according to the results of the KEYNOTE-158 trial presented at the 2020 Gastrointestinal Cancers Symposium.

New Homologous Recombination Deficiency Findings in Pancreatic Cancer Alter Treatment Focus

April 03, 2020

PARP inhibitors following platinum-based chemotherapy as well as immunotherapy combinations have shown early signs of efficacy in metastatic pancreatic cancer with homologous recombination deficiency, according to data presented at the 2020 Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco, California.

Doctors Debate: Is Radiotherapy Still an Essential Component of Neoadjuvant Therapy for Resectable Pancreatic Cancer?

April 01, 2020

In the neoadjuvant setting, physicians treating resectable pancreatic cancer have more treatment options than ever before. Recently, however, the routine use of radiotherapy has been called into question, leading to a debate at the 5th Annual School of Gastrointestinal Oncology, hosted by Physicians’ Education Resource, LLC.

Multidisciplinary Treatment Strategies for Well-Differentiation Neuroendocrine Tumors

April 01, 2020

In an interview with Targeted Oncology at the 5th Annual School of Gastrointestinal Oncology, Jonathan Strosberg, MD explained the importance of having multidisciplinary teams when treating patients with neuroendocrine tumors.